



# Nanocomposite hydrogel microneedles: a theranostic toolbox for personalized medicine

Catarina F. Martins<sup>1</sup> · Clara García-Astrain<sup>2,3</sup> · João Conde<sup>1</sup> · Luis M. Liz-Marzán<sup>2,3,4</sup>

Accepted: 24 January 2024  
© The Author(s) 2024

## Abstract

Due to the severity and high prevalence of cancer, as well as its complex pathological condition, new strategies for cancer treatment and diagnostics are required. As such, it is important to design a toolbox that integrates multiple functions on a single smart platform. Theranostic hydrogels offer an innovative and personalized method to tackle cancer while also considering patient comfort, thereby facilitating future implementation and translation to the clinic. In terms of theranostic systems used in cancer therapy, nanoparticles are widely used as diagnostic and therapeutic tools. Nanoparticles can achieve systemic circulation, evade host defenses, and deliver drugs and signaling agents at the targeted site, to diagnose and treat the disease at a cellular and molecular level. In this context, hydrogel microneedles have a high potential for multifunctional operation in medical devices, while avoiding the complications associated with the systemic delivery of therapeutics. Compared with oral administration and subcutaneous injection, microneedles offer advantages such as better patient compliance, faster onset of action, and improved permeability and efficacy. In addition, they comprise highly biocompatible polymers with excellent degradability and tunable properties. Nanoparticles and microneedles thus offer the possibility to expand the theranostic potential through combined synergistic use of their respective features. We review herein recent advances concerning processing methods and material requirements within the realm of hydrogel microneedles as theranostic platforms, various approaches toward cancer therapy, and the incorporation of nanoparticles for added functionality.

**Keywords** Microneedles · Nanocomposite hydrogels · Theranostics · Cancer

## Introduction

Broadly considered, the term cancer refers to a set of diseases in which malignant cells grow abnormally fast and spread throughout the body. Cancer is the second-leading cause of mortality worldwide. Among many different types, lung cancer is the most frequently diagnosed variety, followed by breast

cancer, prostate cancer, and colorectal cancer [1]. Cancer is considered a heterogeneous disease due to its wide variability, triggered by various endogenous and exogenous factors. Such a heterogeneity leads to a diverse biological presentation, epidemiology, response to treatment, and prognosis [1–4]. Therefore, there is still a need for effective drug delivery strategies that ensure overall therapeutic efficacy. Among the different types of treatment administration, intravenous and oral are preferentially chosen, but even these routes pose issues in terms of drug biodistribution into the target site, associated with poor pharmacokinetics and clearance [5]. In this context, transdermal patches appear as a promising solution, offering a simple and efficient drug delivery strategy. The main concept is related to macroscale delivery systems that can be locally implanted on the tumor tissue, thereby avoiding the complications associated with the systemic delivery of therapeutics. More specifically, microneedles (MNs) are particularly attractive because they are minimally invasive, with better patient compliance and a faster onset of action, thus permitting enhanced drug delivery into the target site, while reducing medical costs [5].

✉ Luis M. Liz-Marzán  
llizmarzan@cicbiomagune.es

<sup>1</sup> ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMSFCM, Universidade NOVA de Lisboa, Lisbon, Portugal

<sup>2</sup> CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastián, Spain

<sup>3</sup> Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y, Nanomedicina (CIBER-BBN), 20014 Donostia-San Sebastián, Spain

<sup>4</sup> Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain

MNs can be used to efficiently deliver both small molecules and macromolecules, such as chemotherapeutics, proteins, and genetic material, along with nanoparticle-based anticancer therapies. Compared with conventional administration and subcutaneous injection, MN patches offer several advantages, such as a controlled delivery rate, low drug concentration in blood, high permeability, reduced toxicity side effects, and avoidance of first-pass hepatic metabolism, with minimal pain and discomfort [6]. In terms of cancer therapy, MNs have been used for localized therapy, enabling controlled release and minimizing systemic side effects, for combination therapy based on its versatility for comprehensive treatment, and for photothermal therapy through the incorporation of nanomaterials allowing localized hyperthermia for selective destruction of cancer cells upon heating. Therefore, MNs open new avenues toward personalized medicine and targeted treatment, thereby improving the effectiveness and patient experience during cancer therapy. Notwithstanding, MNs also present certain limitations, such as the need to ensure biocompatibility to prevent adverse reactions and inflammation, optimization of the loading capacity to guarantee the supply of therapeutic agents for effective treatment, manufacturing scalability, following regulatory considerations to reach clinical translation while ensuring safety and efficacy, as well as improving patient acceptance [6, 7]. In terms of design, MNs require the use of a biocompatible matrix material to obtain a solid pointed structure with sufficient mechanical strength to penetrate the skin and create microchannels that facilitate drug diffusion. The design of the pointed structure should be tailored for different applications. Solid MNs have the advantage of a simpler fabrication and minimum invasiveness compared to traditional drug delivery methods. On the other hand, coated MNs comprise a solid base surrounded by a drug-loaded coating, which gets dissolved upon skin penetration, triggering the release of the therapeutic payload in a more controlled manner. Alternatively, hollow MNs feature an internal microchannel that allows the passage of liquid formulations, and as such their mechanism is based on directly injecting the drug into the desired site, allowing for a more precise delivery action. Finally, dissolving MNs are typically made of a water-soluble material that dissolves upon penetration in the skin, releasing the drug. Dissolving MNs have the advantage of being more patient-friendly because there is no need to remove them after treatment [6, 7].

Among the different types of materials suitable for MN fabrication, hydrogel-forming MNs (HFMs) have gained attention due to their hydrophilic nature, which ensures a sustained release mechanism. Moreover, the versatility in material composition, high loading capacity and ease of fabrication makes hydrogels ideal candidates for MN preparation [8, 9]. These HFMs swell and dissolve upon insertion into the skin, resulting in a more sustained drug release [9]. Hydrogels have a high degree of porosity, which can be tuned through


crosslinking of the constituting polymers, which additionally provides mechanical strength, adhesive properties, stability, and protection of the therapeutic agent. With a highly tunable physical structure, the applications of hydrogels are almost unlimited, rendering them a useful toolbox for biomedical applications and MN fabrication [10, 11]. Regarding cancer research, HFMs are ideal substrates for the integration of diagnostics, therapy, and/or imaging into a single system, which is often referred to as a theranostic platform [12, 13]. Among other advantages, HFMs enable long-term diagnostic capabilities and continuous monitoring of cancer and pharmacokinetics, eventually improving the patient's response to treatment. Additionally, HFMs may even avoid the need for surgery and biopsy collection, thereby reducing the cost and risk associated with invasive methods [14–18].

To improve diagnosis, prevention, and disease treatment, HFMs can also be combined with nanomaterials [19, 20]. The term nanotheranostics refers to the combination of diagnosis, imaging, and therapeutic activity of nanomaterials, integrated simultaneously in a single system to combat a certain disease [21]. This approach not only aids in treatment planning but also enables real-time monitoring of therapeutic responses, thereby facilitating personalized treatments (Fig. 1) [21–23]. Within the rich nanotechnology toolbox for diagnosing and treating cancer, various multifunctional nanocarriers have emerged as versatile tools for a wide array of innovative therapeutic strategies in drug delivery [24]. The advantages of such nanocarriers encompass a high loading efficiency, facilitating combination therapy, ensuring controlled release and prolonged circulation in the body, as well as the ability to target specific sites [25, 26]. Therefore, it remains imperative to discuss the interplay between nanoparticles (NPs) and the host hydrogel, to consider the processing methods employed for nanocomposite HFMs fabrication, and to evaluate their collective impact on the overall performance of the system.

## Hydrogel selection and material requirements

The choice of a specific hydrogel for microneedle applications is a critical design aspect, because it influences the resulting mechanical properties, drug release kinetics, and biocompatibility [27]. The formulation of an ideal MN from hydrogels requires a number of functional features, including the following: a high absorption capacity in saline solutions, a tunable rate of absorption (preferred hydrogel pore size and porosity) depending on the application requirement, highest absorbency under load, lowest soluble content with high resistance to dissolution in water, low cost and ease of fabrication, highest durability and stability in the swelling environment and during storage, tailored biodegradability without the formation of toxic species, pH neutrality after swelling, and absence of color [28–30]. In fact,

**Fig. 1** Schematic view of the term nanotheranostics, comparing the advantages (pros) and drawbacks (cons) of traditional therapies and diagnostic methods versus integrative nanotheranostic approaches in precision medicine, with the representation of hydrogel microneedle systems



the ideal hydrogel for MN formulation should efficiently absorb physiological fluids to ensure that the MNs can swell upon application, thereby facilitating drug release or other functionalities [31]. Depending on the specific therapeutic needs, one might require faster or slower rates of absorption. Factors such as particle size and porosity should be adjustable to fit diverse therapeutic applications. Besides, HFMs should maintain their absorbency when subjected to external pressure, thus ensuring consistent performance irrespective of external conditions. By reducing the presence of soluble components in hydrogels, the potential leaching of unwanted substances during HFM application can be minimized, which is crucial for safety. Indeed, HFMs need to maintain their structure both in a swelling environment and during storage, to ensure their performance while avoiding premature degradation [32–36]. Regarding mechanical properties, the hydrogel should have sufficient rigidity to penetrate the skin or target tissue, but also suitable flexibility to accommodate dynamic movements.

Table 1 summarizes the general specifications to fabricate HFMs for drug delivery. The optimal values for these parameters will depend on the specific requirements of the HFM application, the type of drug to be delivered, and the desired release profile. Conducting in-depth studies and

optimization based on these ranges can help tailor hydrogel formulations for effective and safe drug delivery through microneedles. Finally, the hydrogels must be biocompatible to minimize any adverse reactions or inflammation upon insertion into the tissue, which can be evaluated through *in vitro* assays such as enzymatic degradation tests, cell viability and cytotoxicity assays, as well as *in vivo* patch testing, cytokine expression analysis, histological analysis, and biocompatibility with animal models.

In general, hydrogels can be classified in terms of their source, degree of crosslinking, composition, and charge. Numerous reviews have been published, establishing hydrogel classifications and reporting in detail their characteristics [39, 40]. We focus here on the most common hydrogels employed for HFM fabrication and

**Table 1** Summary of the required properties and their respective ideal ranges for HFM fabrication

Property	Ideal Range	References
Needle length ( $\mu\text{m}$ )	500–800	[9, 37]
Tip diameter ( $\mu\text{m}$ )	60–160	[9, 37]
Insertion force (N)	0.08–3.04	[9, 37]
Gelation time (min)	1–30	[38]

the requirements to achieve the desired characteristics. When developing a hydrogel for HFM fabrication, the most relevant factors are the degree of crosslinking and the polymer source used to form the matrix. Regarding the polymer source, synthetic hydrogels such as poly(vinyl alcohol) (PVA), poly(vinyl pyrrolidone) (PVP), polyacrylic acid (PAA), and poly(N-isopropylacrylamide) (PNIPAAm) have been widely employed for HFM preparation. Synthetic hydrogel-forming polymers have tunable chemical properties but lack inherent fundamental biological cues, thus requiring their conjugation to cell-binding peptides such as arginylglycylaspartic acid (RGD). On the other hand, natural hydrogels such as hyaluronic acid or gelatin retain their native cell-binding sites but have low reproducibility and batch-to-batch variation. Lastly, semi-synthetic hydrogels, such as gelatin methacryloyl (GelMA) or methacrylated hyaluronic acid (HAMA), retain the biocompatibility and bioactive features of the source polymer, while ensuring the necessary mechanical stability and tunability due to rapid crosslinking [41–51]. Other natural polymers obtained from renewable resources, such as chitosan or cellulose derivatives, have been also reported for HFM fabrication because they are non-toxic and carry suitable functional groups for chemical modification [45]. Crosslinking is a crucial step in the fabrication of HFMs because it imparts mechanical strength and stability to the hydrogel structure. Hydrogel crosslinking also offers the possibility to control the release

of therapeutics through fine-tuning the swelling degree of the material. Various crosslinking techniques can be employed to achieve the desired properties in HFMs, which are closely related to the polymer composition. Table 2 summarizes examples of crosslinking strategies for polymers used in HFMs, together with the benefits and drawbacks of each type of polymer [41–51].

## Hydrogel microneedle design and processing methods

When designing and developing a MN patch, it is important to consider geometrical features (length, diameter, tip size, and shape), whether it is a solid, hollow, side-opened, conical, or beveled tip, material composition, fabrication feasibility, application, layout of the arrays, MN density, total number of MN tips, and surface coating. The ultimate design will thus depend on the limitations imposed by the processing method, as well as the mechanical, physical, and chemical properties of the source material [8, 53]. The shape of MNs is an important aspect of MN design because it determines how much force can be applied before it breaks. The diameter and angle of the tip, as well as the height and base dimensions, determine the safe and reliable insertion of the MN into the skin. Generally, a smaller tip diameter, smaller tip angle, as well as a high ratio

**Table 2** Summary of different polymers used for HFMs, their main properties and reported applications

Polymer	Benefits	Drawbacks	Crosslinking	Application	Ref
Gelatin	<ul style="list-style-type: none"> <li>• Ease of fabrication</li> <li>• Highly biocompatible</li> </ul>	<ul style="list-style-type: none"> <li>• Limited drug load</li> </ul>	Physical	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> </ul>	[41]
Hyaluronic acid	<ul style="list-style-type: none"> <li>• Highly biocompatible</li> <li>• Bioresponsive</li> <li>• Promotes skin hydration</li> </ul>	<ul style="list-style-type: none"> <li>• Bioinert</li> <li>• Rapid degradation</li> <li>• Costly</li> </ul>	Physical	<ul style="list-style-type: none"> <li>• Photothermal therapy</li> <li>• Drug delivery</li> <li>• Imaging</li> </ul>	[42–44]
HAMA	<ul style="list-style-type: none"> <li>• Improved degradation</li> <li>• Biocompatible</li> </ul>	<ul style="list-style-type: none"> <li>• Costly</li> </ul>	Photo-crosslinking	<ul style="list-style-type: none"> <li>• Biomarker sensing</li> </ul>	[42]
GelMa	<ul style="list-style-type: none"> <li>• Biocompatible</li> <li>• Sustained drug release</li> <li>• Tuneable mechanical properties</li> </ul>	<ul style="list-style-type: none"> <li>• Bioinert</li> <li>• Limited stability</li> <li>• Potential immunogenicity</li> </ul>	Photo-crosslinking	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> </ul>	[45]
Chitosan	<ul style="list-style-type: none"> <li>• Biocompatible</li> <li>• Adhesive properties</li> </ul>	<ul style="list-style-type: none"> <li>• Limited mechanical properties</li> </ul>	Chemical, enzymatic	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> </ul>	[46]
PAA	<ul style="list-style-type: none"> <li>• Good swelling capacity</li> <li>• Sustained drug release</li> </ul>	<ul style="list-style-type: none"> <li>• Potential skin irritation</li> </ul>	Chemical	<ul style="list-style-type: none"> <li>• Vaccine release</li> </ul>	[47]
PNIPAAm	<ul style="list-style-type: none"> <li>• Thermoresponsive,</li> <li>• Biocompatible</li> <li>• Chemically versatile</li> </ul>	<ul style="list-style-type: none"> <li>• Bioinert</li> <li>• Rapid release</li> </ul>	Chemical	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> </ul>	[48, 49]
PVA	<ul style="list-style-type: none"> <li>• High swelling</li> <li>• Controlled release</li> </ul>	<ul style="list-style-type: none"> <li>• Limited biodegradability</li> </ul>	Chemical	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> <li>• Photothermal therapy</li> </ul>	[50]
PVP	<ul style="list-style-type: none"> <li>• Biocompatible</li> <li>• Adhesive properties</li> </ul>	<ul style="list-style-type: none"> <li>• Limited mechanical properties</li> <li>• Limited biodegradability</li> </ul>	Chemical	<ul style="list-style-type: none"> <li>• Transdermal drug delivery</li> <li>• Immunotherapy</li> </ul>	[51, 52]

between the height and the base width, will result in successful needle insertion [54–56]. Most MNs to date have been fabricated with heights shorter than 1 mm, yet sufficient to access interstitial fluids (ISF), capillary blood, and to deliver therapeutic agents. When inserting MNs in the tissue to create microchannel arrays, it is important to consider some variables that may affect the flow, such as blood viscosity, contact angle, hydrodynamic diameter, and driving forces including surface tension. In addition, due to the elastic nature of tissues and their irregular surface, which varies for each individual, but also with age and body location, the efficient penetration of MNs to the desired depth without fracture and with high accuracy, may require an applicator to facilitate tissue penetration in a controlled and reproducible manner [56].

Shown in Fig. 2 are some examples of the size and shape of HFMs based on HAMA, chitosan, GelMA, PNIPAAm, and PAA-based HFMs [42, 45–49]. HAMA-based HFMs have been reported to exert a maximum force for skin penetration of 0.6 N with 100% swelling ratio (SR) for MNs of 250  $\mu\text{m}$  base width and 850  $\mu\text{m}$  height [42]. For GelMA-based MNs, maximum forces have been reported between 0.9 and 1.9 N, with SR of 50–70%, for MNs of 200  $\mu\text{m}$  base and 600  $\mu\text{m}$  height [45]. As an example of the properties of HFMs made of synthetic hydrogels, maximum forces for tissue penetration of 0.7 N have been reported for PNIPAAm, with tunable release and SRs depending on hydrogel composition [48, 49].

Various methods exist for hydrogel microneedle fabrication, each with its own set of advantages and limitations (see Fig. 3) [27, 53]. The most established and widely accepted method for fabricating HFMs is micro-molding, which offers high reproducibility, convenient and scalable production, as well as cost-effectiveness. Other advantages of this method include low processing temperatures and an insignificant impact on drug activity. For micro-molding, hydrogels are casted into a micro-mold, which provides a precise control over microneedle dimensions and geometry. To ensure higher precision in the geometry and shape of the microneedle structure, laser ablation is often used to create the mold. Compared to other fabrication strategies, laser ablation permits an accurate control over the laser intensity and scanning speed, thereby becoming more versatile [27, 57]. However, micro-molding is limited to simple shapes and requires additional steps for removal of the MNs from the mold.

Photolithography is another useful technique, in which MN patterns are created on a substrate, followed by casting of a hydrogel into these patterns. This method allows a precise placement of the microneedle array, with well-defined microneedle shapes and easy scalability. However, complex and expensive equipment is required, and its use is limited to planar surfaces [58]. Recently, 3D printing has


also emerged as a versatile tool for MN fabrication, involving layer-by-layer printing of the hydrogel to build MNs with controlled geometry. 3D printing offers customization and design flexibility, thereby opening the way to more complex structures. However, limiting factors such as printing speed, materials viscosity, and printability are to be considered, as well as the frequent need for post-processing steps [59]. Drawing lithography, in turn, achieves high precision by directly drawing MNs onto a hydrogel substrate, but it is restricted to specific formulations [60]. Solvent casting and particle leaching allow also for the creation of MNs by casting a hydrogel solution with dissolvable particles, allowing enhanced drug loading but with limited control over pore size [33]. Microfluidic fabrication utilizes controlled fluid flow in microchannels for precise microneedle geometry, but faces challenges in scale-up for mass production [61]. Finally, electrospinning produces nanofiber-based microneedles with increased drug loading, but lacks precise control over needle dimensions [62].


## Hydrogels and nanoparticles—smart platforms for nanotheranostics

Hydrogels and NPs, whether used separately or in combination, offer versatile platforms for nanotheranostics. The hydrogel provides a smart platform for drug delivery with controlled and targeted release of the therapeutic agent, additionally enabling combinatory therapies to address complex diseases, as well as incorporating contrast imaging agents for a theranostic approach [63, 64]. On the other hand, NPs made of polymers, dendrimers, liposomes, metals, and other inorganic materials are often used in nanotheranostics due to their potential therapeutic payload together with the enhanced permeability and retention (EPR) effect [26]. The EPR effect drives NPs to accumulate preferentially in tumors, making them suitable for cancer therapy [65, 66]. Theranostic NPs enable simultaneous imaging and treatment, providing real-time feedback on treatment efficacy and guiding therapeutic decisions.

NPs have excelled as drug delivery carriers by encapsulating small molecules, peptides, proteins, and nucleic acids, being more versatile and carrying higher payloads than conventional drug delivery systems. In cancer therapy, NPs may show a higher selectivity through either passive or active targeting mechanisms, which allow them to overcome some of the inherent limitations of conventional drugs by improving drug localization, enhancing drug solubility, and reducing toxic side effects through controlled release at the target site [67, 68]. Encapsulation of drug-loaded NPs within a hydrogel matrix has been used to prevent rapid drug release, both locally and systemically. NPs can in turn enable selective release by inducing a response in

**Fig. 2** Silk-PAA composite microneedles: optical image (A) and SEM images (B) (scale bar: 500  $\mu\text{m}$ ) (adapted from ref. 47); gelatin-g-PNIPAAm MNs mounted onto PLA solid MNs coated with PVA: optical image (C) and SEM images (D, E) (adapted from ref.48); PNIPAAm-based MNs: optical image (F) and SEM image (G) (adapted from ref. 49); HAMA-based MNs: fluorescence microscopy image (scale bar: 250  $\mu\text{m}$ ) (H) and SEM image (scale bar: 50  $\mu\text{m}$ ) (I, J) (adapted from ref. 42); chitosan-based MNs: optical photos (K) and SEM images (L, M) (adapted from ref. 46); GelMA-based MNs: SEM image (N), bright field microscopy images (O, P), SEM images top view (Q, R). Adapted from ref. [45]





**Fig. 3** Schematic summary of the various fabrication methods used for the fabrication of HFMs for drug delivery. The choice of method depends on the specific hydrogel formulation, the desired MN char-


acteristics, and the intended application. Researchers often select or combine methods based on the requirements of the targeted drug delivery system

the hydrogel matrix under external stimuli. As an example, plasmonic metal NPs can generate heat in response to near-infrared (NIR) light irradiation, in turn inducing changes in the surrounding hydrogel that enhance drug release [69]. In this manner, NPs and hydrogel can improve the overall performance of the system through synergistic effects, such as increased absorption through the tissue of drugs with low

permeability, prevention of particle aggregation, and stimuli responsiveness, contributing to a more specific control of hydrogel drug release [70].

The uniform distribution of NPs within a hydrogel matrix is crucial for applications such as drug delivery, tissue engineering, and sensing, as it ensures consistent and predictable material properties and performance. Summarized in Fig. 4

**Fig. 4** Representation of the main approaches used to obtain hydrogel-nanoparticle conjugates with uniform distribution: (1) hydrogel formation in a nanoparticle suspension, (2) physically embedding nanoparticles in a hydrogel matrix after gelation, (3) reactive nanoparticle formation within a preformed gel, (4) crosslinking using nanoparticles to form hydrogels, (5) gel formation using nanoparticles, polymers, and distinct gelator molecules. Adapted from ref. [68]



are the main approaches that have been reported toward a uniform distribution of NPs in hydrogels [68].

Each of these methods has its own advantages and may be chosen based on specific application requirements together with the properties of the NPs and the hydrogel. Factors to be considered when selecting the appropriate method include the desired NP distribution, NP size and surface properties, compatibility with the hydrogel matrix,

and the overall purpose of the composite material. The simplest method involves the use of a hydrogel-forming monomer solution together with a suspension of NPs. By means of this approach, one can guarantee an even NP distribution throughout the entire hydrogel matrix [23, 24]. The addition of NPs may reinforce the mechanical stability of the starting hydrogel, stabilize the NPs themselves, and provide responsiveness toward external stimuli [71,

**Table 3** Types of NPs used for nanocomposite HFMs and their applications in drug delivery

Nanoparticles	Polymer for HFM	Application	Ref
Polycaprolactone (PCL)	PAA	Enzyme-responsive NPs for wound healing	[73]
Polyethylene oxide (PEO)	Gelatin	Microneedle electrospayed with nanoparticles for skin treatment	[74]
PNIPAAm	PLGA	Hydrogel swelling triggering biodegradable microneedles for transdermal delivery	[31]
PLGA	PMVE/MA	Microneedles with nanoparticles for antitumor and antiviral responses	[75]
Chitosan	PVA	Microneedle-based photothermal therapy to initiate antitumor immunity and sensitize tumors	[76]
Lipid nanoparticles	PLGA	Microneedles for enhanced transcutaneous vaccine delivery	[77]
	PVP	Microneedles for synergistic chemo-immunotherapy	[52]
Gold nanorods	PVA	Light-triggered microneedles for superficial tumor treatment	[78]
	HA	Light-triggered microneedles for human epidermoid cancer treatment	[42]
	PLLA	Light-triggered microneedles for superficial tumor treatment	[79]
Metal oxide NPs	HA	Microneedles to treat tumor tissues by photodynamic therapy and chemotherapy	[80]

72]. In terms of nanocomposite HFMs, Table 3 shows the different platforms used in drug delivery, ranging from polymeric to metal/metal oxide NPs.


To achieve the desired performance, a better understanding of NP–matrix interactions and the mechanisms involved in the formation of these composite systems is needed. Special attention should be paid to the following: effective incorporation of the NP component to maximize therapeutic loading while maintaining the integrity of each component; tunable mechanical performance to match application-specific requirements; biocompatibility, which is essential in all biomedical applications but may be compromised during gelation or degradation; and long-term stability to minimize treatment frequency [81]. Achieving a uniform distribution of NPs in HFMs is thus a multidimensional challenge that requires careful consideration of hydrogel formulation, NP properties, and fabrication methods. Advanced imaging and spectroscopic techniques are valuable tools for characterizing and optimizing NP distribution within the hydrogel matrix, ultimately enhancing the performance of hydrogel microneedle drug delivery systems [81].

## Hydrogel microneedles in cancer therapy

Conventional cancer treatment procedures involve surgery, chemotherapy, and radiotherapy, all of which entail invasive methods, systemic toxicity, and drug resistance. The specific treatment differs for each type and stage of cancer, localization, and medical background of the patient. Surgery is the main approach to tackle

cancer, but it is usually invasive, accompanied by risk of infection, hemorrhage, and complications from anesthesia [3]. Moreover, not all tumors are surgically accessible, and there is always a risk of recurrence if any cancerous cells are left behind. Chemotherapy is a broad and well-established therapeutic approach for cancer treatment that involves the use of drugs that target rapidly dividing cancer cells, to inhibit their growth or destroy them. It is considered a systemic therapy because the drugs circulate throughout the body, affecting cancer cells both at the primary tumor site and in other parts of the body where cancer may have spread (metastasized) [82]. However, chemotherapy often leads to toxic side effects and relapsing of cancer due to drug resistance development, ultimately resulting in a reduced patient quality of life [82]. Consequently, relying solely on a single-agent therapy does not consistently yield a favorable outcome for the cancer patient, and may result in undesirable side effects as well as an increased risk of cancer recurrence [82, 83].

An effective strategy is thus needed to address these challenges, with a better integration of therapies, so that synergistic benefits are effectively achieved, mitigating side effects and overcoming tumor cell resistance. A combined therapy entails three pivotal objectives that a single-agent therapy cannot achieve: (a) it provides a more specific treatment; (b) it reduces side effects, thereby increasing the quality of life of the patient; and (c) it lowers the required treatment dosage [84–86]. In this context, HFMs have emerged as a promising technology in cancer therapy, particularly in combination therapy approaches, including chemotherapy, immunotherapies, and other anticancer treatments (Fig. 5)



**Fig. 5** Representation of nanoparticle-loaded HFMs for cancer therapy. The table shows the main therapies where nanocomposite HFMs are used, detailing their benefits and drawbacks, as a tailored tool for personalized and precision medicine

[86]. Although HFMs have potential applications in various cancer therapies, the following aspects provide them with a specific relevance in melanoma treatment. HFMs are well suited for superficial lesions due to their ability to penetrate the skin at a suitable depth; they are minimally invasive, making them ideal for dermatology and skin cancer treatment [87]. By targeting the affected skin area with suitable therapeutic agents, systemic exposure is minimized and side effects are reduced. Therefore, HFMs can serve a dual purpose by not only delivering therapeutic agents but also enabling minimally invasive biopsy procedures for diagnostic sampling of melanoma lesions. Some hydrogel formulations used in MNs can be designed to respond to specific conditions, such as temperature changes associated with skin cancer, so that controlled drug release occurs selectively at the target site. As an example, HFMs made of hyaluronic acid for melanoma treatment have been reported to enhance the efficacy of immunotherapy, where the release of the antibody is triggered by pH-sensitive polymeric NPs. When the MNs enter the tumor acidic environment self-dissociation of NPs takes place, resulting in a more efficient process than intratumoral injection of free antibodies with the same dose [88].

For solid and superficial cancers, the combination of chemotherapy and photothermal therapy (PTT) can be used to enhance the therapeutic effect and improve treatment outcomes. Whereas chemotherapy acts at both the primary tumor and distant metastatic sites, PTT involves the use of light-absorbing sensitizers (molecules or plasmonic NPs) that have been previously released into or near the tumor [89]. When exposed to laser light of a specific wavelength, the sensitizers release part of the absorbed energy as heat, causing localized hyperthermia and selectively damage to cancer cells. The combination of chemotherapy and PTT is expected to have a synergistic effect, leading to increased cancer cell death. For example, hyperthermia induced by PTT can additionally enhance the uptake and effectiveness of chemotherapeutic drugs in the tumor microenvironment [90].

An appealing system for combined chemo-/photothermal therapy involves the use of HFMs loaded with both NIR-responsive NPs and anticancer drugs, thereby achieving a synergistic antitumoral effect [52]. Another example involves HFMs based on hyaluronic acid loaded with gold nanorods (AuNRs) and doxorubicin (DOX), again to combine the photothermal effect with the anticancer therapeutics, revealing remarkable antitumoral efficacy without any recurrence, after one single treatment [43]. Synergistic combinatory therapy has also been achieved using PCL MNs containing photosensitive molecules and DOX as the chemotherapeutic drug. The support array patch was made of a dissolvable PVA/PVP mixture, so that the MNs could be inserted in the target tissue with no need for surgical procedures, thereby allowing a uniform delivery

of both heat and drugs to the tumor, which was eradicated within 1 week after a single administration with MNs [78].

## Challenges and future perspectives

Although significant progress has been made in the development of HFMs with embedded NPs, the synthesis and in vivo application of this particular type of nanocomposites are still facing multiple challenges. Of note is the clearance of the structure upon complete release of the encapsulated therapeutic agents. Despite the high biocompatibility of the individual components, their prolonged retention poses a risk of adverse effects, such as foreign body responses. This issue may be addressed by utilizing more sophisticated strategies for controlled degradation, potentially involving simultaneous control over polymer cleavage rates, variation of crosslinkers, and the use of homogenous polymer networks. Other challenges include achieving gelation at an optimal time, prior to implantation or in situ. Premature gelation increases the risk of low or uneven incorporation of NPs within the structure, in turn leading to suboptimal delivery of therapeutic payloads. Conversely, delayed gelation poses risks of delivery to undesired areas, rather than specific targeted delivery [34, 40]. Employing smart polymer systems that quickly form a gel in response to a specific stimulus may be a viable approach for addressing this issue. With NP-loaded HFMs, it is also essential to consider the complexity of the biological environment. Applications such as immune modulation and tissue engineering rely on the ability of the platform to interact with individual cells and the microenvironment, both adjacent to and inside the structure itself. As such, platforms designed for these purposes must incorporate components that can correctly interface with the body. Therefore, improving the interface between biomedical devices, such as HFMs and the human body, is crucial for enhancing device performance, safety, and patient comfort. Some strategies to be taken into consideration include surface modification of the needles to enhance biocompatibility by improving tissue interactions and minimizing immune reactions [91].

Needle design and material properties are also crucial to further minimize tissue damage during insertion. Moreover, sterilization and packaging are also important to avoid contamination and biodegradability, reducing the risk of long-term implantation or foreign body responses. Overall, assembling different NPs and hydrogel platforms into superstructures such as HFMs represents a promising methodology for addressing and overcoming the limitations that traditional therapeutics currently have. With continued development and improved understanding, we anticipate that superstructure platforms will become increasingly popular [92]. Besides improving the compatibility of the material with the body,

the integration of various types of NPs can potentially impart novel functionalities to hybrid HFMs. The resulting nanocomposite HFMs can serve to monitor tissues or targeted tumor parameters, such as temperature and pH. For instance, the incorporation of photoluminescent rare earth-based nanothermometers or pH-sensing probes would enable continuous monitoring of the therapeutic treatment. Furthermore, combining different NPs within a single system holds promise for multimodal sensing and imaging capabilities. On the other hand, by introducing piezoelectric particles, HFMs might serve to modulate the mechanical properties of the tumor microenvironment, potentially affecting the mechanobiology of cancer cells and modifying their behavior [93, 94].

## Conclusions

The incorporation of nanomaterials within HFMs represents an attractive approach to tailoring the mechanical properties of hydrogels and/or providing the overall system with responsiveness to mechanical, thermal, magnetic, or electric stimuli. The versatility of both hydrogel and NP composition enables the development of a smart toolbox of HFMs, with the advantages of being minimally invasive and highly biocompatible. Further studies must be carried out to better understand the interactions, at different length scales, between the polymeric chains of hydrogels and the embedded NPs. In the case of drug delivery systems, such studies should include the interactions between the NPs interior and the drug(s) loaded into them. This knowledge will aid in predicting and modulating the mechanical and functional behavior of the composite. Grasping the complex relationship between structure (from nano to macro scale) and resultant properties is foundational. Such an understanding will empower researchers to custom design HFMs tailored for specific applications, be it drug delivery, tissue engineering, or sensing. As research progresses, HFMs are ready to redefine therapeutic interventions, offering solutions that are both efficient and patient-friendly.

**Author contributions** All authors contributed to the study conception and design. The first draft of the manuscript was written by Catarina F. Martins, and all authors commented on various versions of the manuscript. All authors read and approved the final manuscript.

**Funding** This work was supported by an ERC Advanced Grant 787510 4DbioSERS from the European Research Council. C.F.M. acknowledges the National funding by FCT, Foundation for Science and Technology, through an individual research grant (2022.11436.BD). C.G.-A. acknowledges a Juan de la Cierva Incorporación Fellowship from the Spanish Ministry of Science, Innovation and Universities (IJC2019-040827-I). J.C. acknowledge the European Research Council Starting Grant (ERC-StG-2019-848325).

## Declarations

**Ethics approval** N/A.

**Consent to participate** N/A.

**Consent to publish** N/A.

**Competing interests** J. C. is a co-founder and shareholder of Targ-Tex S.A. – Targeted therapeutics for Glioblastoma Multiforme. J.C. is also a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394–424. <https://doi.org/10.3322/caac.21492>.
2. Collaboration GB of D 2019 C. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. *JAMA Oncol.* 2010; <https://doi.org/10.1001/jamaoncol.2021.6987>.
3. Bertram JS. The molecular biology of cancer. *Mol Aspects Med.* 2000;21:167–223. <https://www.sciencedirect.com/science/article/pii/S0098299700000078>.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144:646–74. <https://www.sciencedirect.com/science/article/pii/S0092867411001279>.
5. Moreira AF, Rodrigues CF, Jacinto TA, Miguel SP, Costa EC, Correia IJ. Microneedle-based delivery devices for cancer therapy: a review. *Pharmacol Res.* 2019;148:104438. <https://www.sciencedirect.com/science/article/pii/S1043661819316329>.
6. Rad ZF, Prewett PD, Davies GJ. An overview of microneedle applications, materials, and fabrication methods. *Beilstein J Nanotechnol.* 2021;12:1034–46.
7. Ahmed EM. Hydrogel: Preparation, characterization, and applications: a review. *J Adv Res.* 2015;6:105–21. <https://www.sciencedirect.com/science/article/pii/S2090123213000969>.
8. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. *Biomed Pharmacother.* 2019;109:1249–58. <https://doi.org/10.1016/j.biopha.2018.10.078>.
9. Turner JG, White LR, Estrela P, Leese HS. Hydrogel-forming microneedles: current advancements and future trends. *Macromol Biosci.* 2021;21:2000307 <https://doi.org/10.1002/mabi.202000307>.

10. Mondal S, Das S, Nandi AK. A review on recent advances in polymer and peptide hydrogels. *Soft Matter*. 2020;16:1404–54. <https://doi.org/10.1039/C9SM02127B>.
11. Zhang Y, Huang Y. Rational design of smart hydrogels for biomedical applications. *Front Chem*. 2021;8:615665. <https://www.frontiersin.org/articles/10.3389/fchem.2020.615665>.
12. Sikdar P, Uddin MdM, Dip TM, Islam S, Hoque MdS, Dhar AK, et al. Recent advances in the synthesis of smart hydrogels. *Mater Adv*. 2021;2:4532–73. <https://doi.org/10.1039/D1MA00193K>.
13. Madduma-Bandarage USK, Madihally SV. Synthetic hydrogels: synthesis, novel trends, and applications. *J Appl Polym Sci*. 2021;138:50376. <https://doi.org/10.1002/app.50376>.
14. Dosta P, Puigmal N, Cryer AM, Rodríguez AL, Scott E, Weissleder R, et al. Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. *Theranostics*. 2023;13:1–15. <https://www.thno.org/v13p0001.htm>.
15. Khan S, Hasan A, Attar F, Babadaei MMN, Zeinabad HA, Salehi M, et al. Diagnostic and drug release systems based on microneedle arrays in breast cancer therapy. *Journal of Controlled Release*. 2021;338:341–57. <https://www.sciencedirect.com/science/article/pii/S0168365921004429>.
16. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. *Nano Lett*. 2016;16:2334–40. <https://doi.org/10.1021/acs.nanolett.5b05030>.
17. Park W, Maeng S-W, Mok JW, Choi M, Cha HJ, Joo C-K, et al. Hydrogel microneedles extracting exosomes for early detection of colorectal cancer. *Biomacromol*. 2023;24:1445–52. <https://doi.org/10.1021/acs.biomac.2c01449>.
18. Huang S, Liu H, Huang S, Fu T, Xue W, Guo R. Dextran methacrylate hydrogel microneedles loaded with doxorubicin and trametinib for continuous transdermal administration of melanoma. *Carbohydr Polym*. 2020;246:116650. <https://www.sciencedirect.com/science/article/pii/S0144861720308249>.
19. Yang J, Zhang H, Hu T, Xu C, Jiang L, Shrike Zhang Y, et al. Recent advances of microneedles used towards stimuli-responsive drug delivery, disease theranostics, and bioinspired applications. *Chem Eng J*. 2021;426:130561. <https://doi.org/10.1016/j.cej.2021.130561>.
20. Amarnani R, Shende P. Microneedles in diagnostic, treatment and theranostics: an advancement in minimally-invasive delivery system. *Biomed Microdevices*. 2021;24:4. <https://doi.org/10.1007/s10544-021-00604-w>.
21. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. *Adv Drug Deliv Rev*. 2006;58:1456–9. <https://www.sciencedirect.com/science/article/pii/S0169409X06001736>.
22. Chakraborty A, Roy A, Ravi SP, Paul A. Exploiting the role of nanoparticles for use in hydrogel-based bioprinting applications: concept, design, and recent advances. *Biomater Sci*. 2021;9:6337–54. <https://doi.org/10.1039/D1BM00605C>.
23. Nunes D, Andrade S, Ramalho MJ, Loureiro JA, Pereira MC. Polymeric nanoparticles-loaded hydrogels for biomedical applications a systematic review on in vivo findings. *Polymers*. 2022;14:1010. <https://doi.org/10.3390/polym14051010>.
24. Jiang Y, Krishnan N, Heo J, Fang RH, Zhang L. Nanoparticle-hydrogel superstructures for biomedical applications. *J Control Release*. 2020;324:505–21. <https://www.sciencedirect.com/science/article/pii/S0168365920303187>.
25. Mendes BB, Sousa DP, Coniot J, Conde J. Nanomedicine-based strategies to target and modulate the tumor microenvironment. *Trends Cancer*. 2021;7:847–62. <https://www.sciencedirect.com/science/article/pii/S2405803321001023>.
26. Mendes BB, Coniot J, Avital A, Yao D, Jiang X, Zhou X, et al. Nanodelivery of nucleic acids. *Nature Reviews Methods Primers*. 2022;2:24. <https://doi.org/10.1038/s43586-022-00104-y>.
27. Luo X, Yang L, Cui Y. *Microneedles: materials, fabrication, and biomedical applications*. Biomed Microdevices: Springer; 2023.
28. Correa S, Grosskopf AK, Lopez Hernandez H, Chan D, Yu AC, Stapleton LM, et al. Translational applications of hydrogels. *Chem Rev*. 2021;121:11385–457. <https://doi.org/10.1021/acs.chemrev.0c01177>.
29. Kaith BS, Singh A, Sharma AK, Sud D. Hydrogels: synthesis, classification, properties and potential applications—a brief review. *J Polym Environ*. 2021;29:3827–41. <https://doi.org/10.1007/s10924-021-02184-5>.
30. Aswathy SH, Narendrakumar U, Manjubala I. Commercial hydrogels for biomedical applications. *Heliyon*. 2020;6:e03719. <https://doi.org/10.1016/j.heliyon.2020.e03719>.
31. Kim M, Jung B, Park JH. Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin. *Biomaterials*. 2012;33:668–78. <https://www.sciencedirect.com/science/article/pii/S0142961211011501>.
32. Sun Z, Song C, Wang C, Hu Y, Wu J. Hydrogel-based controlled drug delivery for cancer treatment: a review. *Mol Pharm*. 2020;17:373–91.
33. Peng K, Vora LK, Domínguez-Robles J, Naser YA, Li M, Larrañeta E, et al. Hydrogel-forming microneedles for rapid and efficient skin deposition of controlled release tip-implants. *Mater Sci Eng: C*. 2021;127. <https://www.sciencedirect.com/science/article/pii/S0928493121003660>.
34. Liu Y, Huang T, Qian Z, Chen W. Extensible and swellable hydrogel-forming microneedles for deep point-of-care sampling and drug deployment. *Chin Chem Lett*. 2023;34: 108103. <https://doi.org/10.1016/j.ccllet.2022.108103>.
35. Oliva N, Conde J, Wang K, Artzi N. Designing hydrogels for on-demand therapy. *Acc Chem Res*. 2017;50:669–79.
36. Hong X, Wu Z, Chen L, Wu F, Wei L, Yuan W. Hydrogel microneedle arrays for transdermal drug delivery. *Nanomicro Lett*. 2014;6:191–9. <https://doi.org/10.1007/BF03353783>.
37. Römgens AM, Bader DL, Bouwstra JA, Baaijens FPT, Oomens CWJ. Monitoring the penetration process of single microneedles with varying tip diameters. *J Mech Behav Biomed Mater*. 2014;40:397–405. <https://www.sciencedirect.com/science/article/pii/S1751616114002999>.
38. Azizi Machekposhti S, Khanna S, Shukla S, Narayan R. Microneedle fabrication methods and applications. *MRS Commun*. 2023;13:212–24. <https://doi.org/10.1557/s43579-023-00355-0>.
39. Ullah F, Othman MBH, Javed F, Ahmad Z, Akil HMD. Classification, processing and application of hydrogels a review. *Mater Sci Eng: C*. 2015;57:414–33. <https://www.sciencedirect.com/science/article/pii/S0928493115302393>.
40. Hoffman AS. Hydrogels for biomedical applications. *Adv Drug Deliv Rev*. 2012;64:18–23. <https://doi.org/10.1016/j.addr.2012.09.010>.
41. Mushtaq F, Raza ZA, Batool SR, Zahid M, Onder OC, Rafique A, et al. Preparation, properties, and applications of gelatin-based hydrogels (GHs) in the environmental, technological, and biomedical sectors. *Int J Biol Macromol*. 2022;218:601–33. <https://www.sciencedirect.com/science/article/pii/S0141813022016002>.
42. Zheng H, GhavamiNejad A, GhavamiNejad P, Samarikhajaj M, Giacca A, Poudineh M. Hydrogel microneedle-assisted assay integrating aptamer probes and fluorescence detection for reagentless biomarker quantification. *ACS Sens*. 2022;7:2387–99. <https://doi.org/10.1021/acssensors.2c01033>.
43. Hao Y, Chen Y, Lei M, Zhang T, Cao Y, Peng J, et al. Near-infrared responsive pegylated gold nanorod and doxorubicin loaded dissolvable hyaluronic acid microneedles for human epidermoid cancer therapy. *Adv Ther (Weinh)*. 2018;1:1800008. <https://doi.org/10.1002/adtp.201800008>.

44. Lee Y, Kang T, Cho HR, Lee GJ, Park OK, Kim S, et al. Localized delivery of theranostic nanoparticles and high-energy photons using microneedles-on-bioelectronics. *Adv Mater*. 2021;33:2100425. <https://doi.org/10.1002/adma.202100425>.
45. Zeng Z, Jiang G, Liu T, Song G, Sun Y, Zhang X, et al. Fabrication of gelatin methacryloyl hydrogel microneedles for transdermal delivery of metformin in diabetic rats. *Bioelectrochim Acta*. 2021;4:902–11.
46. Wei H, Liu S, Tong Z, Chen T, Yang M, Guo Y, et al. Hydrogel-based microneedles of chitosan derivatives for drug delivery. *React Funct Polym*. 2022;172:105200. <https://www.sciencedirect.com/science/article/pii/S1381514822000426>.
47. DeMuth PC, Min Y, Irvine DJ, Hammond PT. Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization. *Adv Healthc Mater*. 2014;3:47–58. <https://doi.org/10.1002/adhm.201300139>.
48. Li JY, Feng YH, He YT, Hu LF, Liang L, Zhao ZQ, et al. Thermosensitive hydrogel microneedles for controlled transdermal drug delivery. *Acta Biomater*. 2022;153:308–19. <https://www.sciencedirect.com/science/article/pii/S1742706122005451>.
49. Chen S, Matsumoto H, Moro-oka Y, Tanaka M, Miyahara Y, Suganami T, et al. Microneedle-array patch fabricated with enzyme-free polymeric components capable of on-demand insulin delivery. *Adv Funct Mater*. 2019;29:1807369. <https://doi.org/10.1002/adfm.201807369>.
50. Moreira AF, Rodrigues CF, Jacinto TA, Miguel SP, Costa EC, Correia IJ. Poly (vinyl alcohol)/chitosan layer-by-layer microneedles for cancer chemo-photothermal therapy. *Int J Pharm*. 2020;576:118907. <https://www.sciencedirect.com/science/article/pii/S0378517319309524>.
51. Elim D, Fitri AMN, Mahfud MAS, Afika N, Sultan NAF, Hijrah, et al. Hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from polyethylene glycol reservoir: an ex vivo proof of concept study. *Colloids Surf B Biointerfaces*. 2023;222:113018. <https://www.sciencedirect.com/science/article/pii/S0927776522007020>.
52. Lan X, Zhu W, Huang X, Yu Y, Xiao H, Jin L, et al. Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. *Nanoscale*. 2020;12:18885–98. <https://doi.org/10.1039/D0NR04213G>.
53. Aldawood FK, Andar A, Desai S. A comprehensive review of microneedles: types, materials, processes, characterizations and applications. *Polymers*. 2021;13:2815. <https://doi.org/10.3390/polym13162815>.
54. Xu J, Xu D, Xuan X, He H. Advances of microneedles in biomedical applications. *Molecules*. 2021;26:5912.
55. Wu Y, Tang Z, Ma S, Du L. The promising application of hydrogel microneedles in medical application. *J Pharm Pharmacol*. 2023;75:1011–20. <https://doi.org/10.1093/jpp/rgad058>.
56. Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. *J Pharm Investig*. 2021;51:503–17. <https://doi.org/10.1007/s40005-021-00512-4>.
57. Nejad HR, Sadeqi A, Kiaee G, Sonkusale S. Low-cost and cleanroom-free fabrication of microneedles. *Microsyst Nanoeng*. 2018;4:17073. <https://doi.org/10.1038/micronano.2017.73>.
58. Kathuria H, Kang K, Cai J, Kang L. Rapid microneedle fabrication by heating and photolithography. *Int J Pharm*. 2020;575:118992. <https://www.sciencedirect.com/science/article/pii/S0378517319310531>.
59. Wu M, Zhang Y, Huang H, Li J, Liu H, Guo Z, et al. Assisted 3D printing of microneedle patches for minimally invasive glucose control in diabetes. *Materials Science and Engineering: C*. 2020;117:111299. <https://www.sciencedirect.com/science/article/pii/S0928493120332173>.
60. Chen Z, Ren L, Li J, Yao L, Chen Y, Liu B, et al. Rapid fabrication of microneedles using magnetorheological drawing lithography. *Acta Biomater*. 2018;65:283–91. <https://www.sciencedirect.com/science/article/pii/S174270611730658X>.
61. He R, Niu Y, Li Z, Li A, Yang H, Xu F, et al. A hydrogel microneedle patch for point-of-care testing based on skin interstitial fluid. *Adv Healthc Mater*. 2020;9:1901201. <https://doi.org/10.1002/adhm.201901201>.
62. Chi J, Zhang X, Chen C, Shao C, Zhao Y, Wang Y. Antibacterial and angiogenic chitosan microneedle array patch for promoting wound healing. *Bioact Mater*. 2020;5:253–9. <https://www.sciencedirect.com/science/article/pii/S2452199X20300165>.
63. Conde J, Oliva N, Zhang Y, Artzi N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. *Nat Mater*. 2016;15:1128–38. <https://doi.org/10.1038/nmat4707>.
64. Zhong R, Talebian S, Mendes BB, Wallace G, Langer R, Conde J, et al. Hydrogels for RNA delivery. *Nat Mater*. 2023;22:818–31. <https://doi.org/10.1038/s41563-023-01472-w>.
65. Carvalho A, Fernandes AR, Baptista PV. Nanoparticles as delivery systems in cancer therapy. In: *Applications of targeted nano drugs and delivery systems*. Elsevier Inc; 2019. <https://doi.org/10.1016/B978-0-12-814029-1.00010-7>.
66. Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. *Cancer Gene Ther*. 2017;24:233–43. <https://doi.org/10.1038/cgt.2017.16>.
67. Guillot AJ, Martínez-Navarrete M, Zinchuk-Mironova V, Melero A. Microneedle-assisted transdermal delivery of nanoparticles: recent insights and prospects. *WIREs Nanomed Nanobiotechnol*. 2023;15:e1184. <https://doi.org/10.1002/wnan.1884>.
68. Thoniyot P, Tan MJ, Karim AA, Young DJ, Loh XJ. Nanoparticle–hydrogel composites: concept, design, and applications of these promising, multi-functional materials. *Advanced Science*. 2015;2:1400010. <https://doi.org/10.1002/advs.201400010>.
69. Bastiancich C, Danhier P, Pr at V, Danhier F. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. *J Controlled Release*. 2016;243:29–42. <https://www.sciencedirect.com/science/article/pii/S0168365916305442>.
70. Chen X, Mendes BB, Zhuang Y, Conniot J, Mercado Argandona S, Melle F, et al. A fluorinated BODIPY-based zirconium metal–organic framework for in vivo enhanced photodynamic therapy. *J Am Chem Soc*. 2024; <https://doi.org/10.1021/jacs.3c12416>.
71. Jiang X, Zhao H, Li W. Microneedle-mediated transdermal delivery of drug-carrying nanoparticles. *Front Bioeng Biotechnol*. 2022;10:840395. <https://doi.org/10.3389/fbioe.2022.840395>.
72. Chen M, Quan G, Sun Y, Yang D, Pan X, Wu C. Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery. *J Control Release*. 2020;325:163–75.
73. Mir M, Permana AD, Tekko IA, McCarthy HO, Ahmed N, Asim ur, et al. Microneedle liquid injection system assisted delivery of infection responsive nanoparticles a promising approach for enhanced site-specific delivery of carvacrol against polymicrobial biofilms-infected wounds. *Int J Pharm*. 2020;587:119643. <https://www.sciencedirect.com/science/article/pii/S037851732030627X>.
74. Tort S, Mutlu Agardan NB, Han D, Steckl AJ. In vitro and in vivo evaluation of microneedles coated with electrosprayed micro/nanoparticles for medical skin treatments. *J Microencapsul*. 2020;37:517–27. <https://doi.org/10.1080/02652048.2020.1809725>.
75. Zaric M, Lyubomska O, Touzelet O, Poux C, Al-Zahrani S, Fay F, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, l-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. *ACS Nano*. 2013;7:2042–55.
76. Chen M, Quan G, Wen T, Yang P, Qin W, Mai H, et al. Cold to hot: binary cooperative microneedle array-amplified photoimmunotherapy for eliciting antitumor immunity and the abscopal

- effect. *ACS Appl Mater Interfaces*. 2020;12:32259–69. <https://doi.org/10.1021/acsami.0c05090>.
77. DeMuth PC, Moon JJ, Suh H, Hammond PT, Irvine DJ. Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. *ACS Nano*. 2012;6:8041–51. <https://doi.org/10.1021/nl302639r>.
  78. Chen M-C, Lin Z-W, Ling M-H. Near-infrared light-activatable microneedle system for treating superficial tumors by combination of chemotherapy and photothermal therapy. *ACS Nano*. 2016;10:93–101. <https://doi.org/10.1021/acsnano.5b05043>.
  79. Hao Y, Dong M, Zhang T, Peng J, Jia Y, Cao Y, et al. novel approach of using near-infrared responsive PEGylated gold nanorod coated poly(l-lactide) microneedles to enhance the antitumor efficiency of docetaxel-loaded MPEG-PDLLA micelles for treating an A431 tumor. *ACS Appl Mater Interfaces*. 2017;9:15317–27. <https://doi.org/10.1021/acsami.7b03604>.
  80. Lee Y, Kang T, Cho HR, Lee GJ, Park OK, Kim S, et al. Localized delivery of theranostic nanoparticles and high-energy photons using microneedles-on-bioelectronics. *Adv Mater*. 2021;33:e2100425. <https://doi.org/10.1002/adma.202100425>.
  81. Zaragoza J, Asuri P. Exploring the effects of nanoparticle incorporation on the mechanical properties of hydrogels. *Proc West Mark Ed Assoc Conf*. 2018;3:2.
  82. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. *Nat Rev Cancer*. 2005;5:65–72. <https://doi.org/10.1038/nrc1529>.
  83. DeVita VT, Chu E. A history of cancer chemotherapy. *Cancer Res*. 2008;68:8643–53.
  84. Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. *Nat Rev Drug Discov*. 2023;22:213–34. <https://doi.org/10.1038/s41573-022-00615-z>.
  85. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy – strategies and perspectives. *J Controlled Release*. 2016;240:489–503. <https://www.sciencedirect.com/science/article/pii/S0168365916303777>.
  86. Li Z, Chen Y, Yang Y, Yu Y, Zhang Y, Zhu D. Recent advances in chemo-photothermal combination therapy for improving cancer treatment. 2019;7:1–19. <https://doi.org/10.3389/fbioe.2019.00293>.
  87. Huang Y, Lai H, Jiang J, Xu X, Zeng Z, Ren L, et al. pH-activatable oxidative stress amplifying dissolving microneedles for combined chemo-photodynamic therapy of melanoma. *Asian J Pharm Sci*. 2022;17:679–96. <https://www.sciencedirect.com/science/article/pii/S1818087622000836>.
  88. Wang M, Li X, Du W, Sun M, Ling G, Zhang P. Microneedle-mediated treatment for superficial tumors by combining multiple strategies. *Drug Deliv Transl Res*. 2023;13:1600–20. <https://doi.org/10.1007/s13346-023-01297-9>.
  89. Nam JM, Liz-Marzán L, Halas N. Chemical nanoplasmonics: emerging interdisciplinary research field at crossroads between nanoscale chemistry and plasmonics. *Acc Chem Res*. 2019;52:2995–6. <https://doi.org/10.1021/acs.accounts.9b00504>.
  90. Abbasian M, Mahmoodzadeh F, Salehi R, Amirshaghghi A. Chemo-photothermal therapy of cancer cells using gold nanorod-cored stimuli-responsive triblock copolymer. *New J Chem*. 2017;41:12777–88. <https://doi.org/10.1039/C7NJ02504A>.
  91. Yuk H, Wu J, Zhao X. Hydrogel interfaces for merging humans and machines. *Nat Rev Mater*. 2022;7:935–52. <https://doi.org/10.1038/s41578-022-00483-4>.
  92. Vashist A, Vashist A, Gupta YK, Ahmad S. Recent advances in hydrogel based drug delivery systems for the human body. *J Mater Chem B*. 2014;2:147–66. <https://doi.org/10.1039/C3TB21016B>.
  93. Brasiliense V, Park JE, Berns EJ, Van Duyne RP, Mrksich M. Surface potential modulation as a tool for mitigating challenges in SERS-based microneedle sensors. *Sci Rep*. 2022;12:15929. <https://doi.org/10.1038/s41598-022-19942-7>.
  94. O'Mahony C, Hilliard L, Kosch T, Bocchino A, Sulas E, Kenthao A, et al. Accuracy and feasibility of piezoelectric inkjet coating technology for applications in microneedle-based transdermal delivery. *Microelectron Eng*. 2017;172:19–25. <https://www.sciencedirect.com/science/article/pii/S0167931717300746>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.